Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Skin imprints to provide noninvasive metabolic profiling of COVID-19 patients

Jeany Delafiori, Rinaldo Focaccia Siciliano, Arthur Noin de Oliveira, José Carlos Nicolau, Geovana Manzan Sales, Talia Falcão Dalçóquio, Estela Natacha Brandt Busanello, Adriana Eguti, Diogo Noin de Oliveira, Adriadne Justi Bertolin, Luiz Augusto dos Santos, Rocío Salsoso, Fabiana G Marcondes-Braga, Nelson Durán, Maurício Wesley Perroud Júnior, Ester Cerdeira Sabino, Leonardo Oliveira Reis, Wagner José Fávaro, Rodrigo Ramos Catharino
doi: https://doi.org/10.1101/2021.04.17.21255518
Jeany Delafiori
1Innovare Biomarkers Laboratory, School of Pharmaceutical Sciences, University of Campinas, Campinas, Brazil - Rua Cinco de Junho, 350 - 13083-970 - Cidade Universitária Zeferino Vaz, Campinas/SP - Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rinaldo Focaccia Siciliano
2Clinical Division of Infectious and Parasitic Diseases, University of São Paulo Medical School, Brazil - Av. Dr. Arnaldo, 455 - 01246-903 - Cerqueira César, São Paulo/SP, Brazil
3Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil - Av. Dr. Enéas de Carvalho Aguiar, 44 - 05403-900 – Cerqueira César, São Paulo/SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arthur Noin de Oliveira
1Innovare Biomarkers Laboratory, School of Pharmaceutical Sciences, University of Campinas, Campinas, Brazil - Rua Cinco de Junho, 350 - 13083-970 - Cidade Universitária Zeferino Vaz, Campinas/SP - Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
José Carlos Nicolau
3Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil - Av. Dr. Enéas de Carvalho Aguiar, 44 - 05403-900 – Cerqueira César, São Paulo/SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geovana Manzan Sales
1Innovare Biomarkers Laboratory, School of Pharmaceutical Sciences, University of Campinas, Campinas, Brazil - Rua Cinco de Junho, 350 - 13083-970 - Cidade Universitária Zeferino Vaz, Campinas/SP - Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Talia Falcão Dalçóquio
3Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil - Av. Dr. Enéas de Carvalho Aguiar, 44 - 05403-900 – Cerqueira César, São Paulo/SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Estela Natacha Brandt Busanello
1Innovare Biomarkers Laboratory, School of Pharmaceutical Sciences, University of Campinas, Campinas, Brazil - Rua Cinco de Junho, 350 - 13083-970 - Cidade Universitária Zeferino Vaz, Campinas/SP - Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adriana Eguti
4Sumaré State Hospital, Sumaré, Brazil - Av. da Amizade, 2400 - 13175-490 - Jardim Bela Vista, Sumaré/SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diogo Noin de Oliveira
1Innovare Biomarkers Laboratory, School of Pharmaceutical Sciences, University of Campinas, Campinas, Brazil - Rua Cinco de Junho, 350 - 13083-970 - Cidade Universitária Zeferino Vaz, Campinas/SP - Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adriadne Justi Bertolin
3Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil - Av. Dr. Enéas de Carvalho Aguiar, 44 - 05403-900 – Cerqueira César, São Paulo/SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luiz Augusto dos Santos
5Paulínia Municipal Hospital, Paulínia, Brazil - Rua Miguel Vicente Cury, 100 - 13140-000 - Nova Paulínia, Paulínia/SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rocío Salsoso
3Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil - Av. Dr. Enéas de Carvalho Aguiar, 44 - 05403-900 – Cerqueira César, São Paulo/SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabiana G Marcondes-Braga
3Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil - Av. Dr. Enéas de Carvalho Aguiar, 44 - 05403-900 – Cerqueira César, São Paulo/SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nelson Durán
6Laboratory of Urogenital Carcinogenesis and Immunotherapy, University of Campinas, Campinas, Brazil - Av. Bertrand Russel, s/n - 13083-865 – Cidade Universitária Zeferino Vaz, Campina/SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maurício Wesley Perroud Júnior
4Sumaré State Hospital, Sumaré, Brazil - Av. da Amizade, 2400 - 13175-490 - Jardim Bela Vista, Sumaré/SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ester Cerdeira Sabino
7Institute of Tropical Medicine, University of São Paulo, São Paulo, Brazil - Avenida Dr. Enéas Carvalho de Aguiar, 470 05403-000 – Cerqueira César, São Paulo/SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leonardo Oliveira Reis
8UroScience Laboratory, University of Campinas, Campinas, Brazil - Rua Tessália Vieira de Camargo, 126 - 13083-887 - Cidade Universitária Zeferino Vaz, Campinas/SP, Brazil
9Center for Life Sciences, Pontifical Catholic University of Campinas, PUC-Campinas, Brazil - Av. John Boyd Dunlop, s/n - 13060-904 - Jd. Ipaussurama Campinas/SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wagner José Fávaro
6Laboratory of Urogenital Carcinogenesis and Immunotherapy, University of Campinas, Campinas, Brazil - Av. Bertrand Russel, s/n - 13083-865 – Cidade Universitária Zeferino Vaz, Campina/SP, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rodrigo Ramos Catharino
1Innovare Biomarkers Laboratory, School of Pharmaceutical Sciences, University of Campinas, Campinas, Brazil - Rua Cinco de Junho, 350 - 13083-970 - Cidade Universitária Zeferino Vaz, Campinas/SP - Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rrc{at}unicamp.br
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

As the current COVID-19 pandemic progresses, more symptoms and signals related to how the disease manifests in the human body arise in the literature. Skin lesions and coagulopathies may be confounding factors on routine care and patient management. We analyzed the metabolic and lipidic profile of the skin from COVID-19 patients using imprints in silica plates as a non-invasive alternative, in order to better understand the biochemical disturbances caused by SARS-CoV-2 in the skin. One hundred and one patients (64 COVID-19 positive patients and 37 control patients) were enrolled in this cross-sectional study from April 2020 to June 2020 during the first wave of COVID-19 in São Paulo, Brazil. Fourteen biomarkers were identified related to COVID-19 infection (7 increased and 7 decreased in COVID-19 patients). Remarkably, oleamide has shown promising performance, providing 79.0% of sensitivity on a receiver operating characteristic curve model. Species related to coagulation and immune system maintenance such as phosphatidylserines were decreased in COVID-19 patients; on the other hand, cytokine storm and immunomodulation may be affected by molecules increased in the COVID-19 group, particularly primary fatty acid amides and N-acylethanolamines, which are part of the endocannabinoid system. Our results show that skin imprints may be a useful, noninvasive strategy for COVID-19 screening, by electing a pool of biomarkers with diagnostic potential.

  • Mass spectrometry
  • COVID-19
  • skin imprint
  • metabolomics
  • SARS-CoV-2

INTRODUCTION

Over a year after the global pandemic was announced, the use of non-pharmaceutical interventions, such as diagnostic methods, use of masks, hygiene and social distancing remain essential to prevent viral transmission. Meanwhile, research and initiatives to obtain more information regarding COVID-19 pathophysiological mechanisms are still ongoing1. Many efforts to understand the pathogenic mechanisms of SARS-CoV-2 infection are based on human metabolic evaluation, which has been showing the involvement of an intense immune response, as well as dysfunctional coagulation and inflammation patterns2. Several studies employing “omics” approaches indicate altered expression of proteins and disrupted lipid metabolism3,4, suggesting the applicability of metabolite investigation at proteomic4, metabolomic4–10 and lipidomic3,9–13 levels. Most contributions employed human samples with established clinical importance, such as plasma5,8–10, serum3,4,13, and saliva7. Nevertheless, novel approaches such as nasal excretion11, exhaled breath6, and sebum12 are under investigation as potential sources of biomarkers that discriminate COVID-19 for diagnosis, and especially for prognosis purposes. Spick et al. (2021) demonstrated that triacylglycerides alterations in sebum lipidome have the potential to be used as a screening test for COVID-19 12. Consequently, the broad range of disrupted metabolites observed in such diverse sample types highlights the comprehensive spectrum of the infection manifestations.

The distribution of SARS-CoV-2 cell entry receptor assists in characterizing COVID-19’s diversity of symptoms that portray multi-organ involvement14. ACE2 (angiotensin-converting enzyme 2) was identified as a crucial receptor for SARS-CoV-2 binding and cell entry14,15. High levels of ACE2 expression are present in different cell types of multiple organs, such as oral cavity, lungs, gastrointestinal tract, and even keratinocytes in the skin14,15. When intact, skin is not considered a gateway for the virus; thus, skin contacts have not been determined as a SARS-CoV-2 transmission route. Conversely, skin lesions have been reported in several cohorts as an underlying manifestation of COVID-19, including in asymptomatic cases16,17. The most common observed skin manifestations were erythematous-violaceous lesions, chilblain-like acral lesions, erythematous rash, urticarial rash, papulovesicular exanthem, and purpuric lesions that might be associated with the overall inflammatory state, and altered thrombotic and coagulation patterns due to COVID-1914,16,17.

In clinical practice, skin manifestations are rare when compared to other symptoms, and are usually not considered as the first signs of COVID-1916. However, sampling metabolites found on normal skin surfaces may offer a powerful resource for the development of rapid and noninvasive diagnostic methods that bear minimal discomfort for the patients. Previous literature brings contributions where approaches using skin imprint in silica plates coupled with mass spectrometry were used to provide metabolic insights on leprosy18 and cystic fibrosis19. In addition to the potential for diagnosis, information on metabolic alterations present on normal skin surfaces during SARS-CoV-2 infection are still incipient and may help the scientific community to better understand the pathophysiology of COVID-1912. With this aim, we enrolled a cohort of 101 subjects divided into positive and negative for COVID-19 and used a clean, simple, and rapid method for skin imprint samples collection using silica plates to assess biomarkers associated with COVID-19 pathology using mass spectrometry and untargeted metabolomics.

EXPERIMENTAL SECTION

Study design

Patients were recruited at Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (HCFMUSP) localized in São Paulo city in Brazil from April to June 2020. The study was conducted according to principles expressed in the Declaration of Helsinki. Ethical approval was given by Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - HCFMUSP ethics committee (CAAE 32077020.6.0000.0005), and a signed consent form was collected from participants before enrolment.

Adult patients (aged 18 and over), with one or more clinical symptoms for SARS-CoV-2 infection in the last 7 days (fever, dry cough, dyspnea, and/or malaise) were eligible, recruited and tested for SARS-CoV-2 infection using nasopharyngeal samples for gold-standard RT-PCR following local protocol based on Charité and WHO recommendations20. Following these procedures, enrolled participants (n = 101) were separated into positive (COVID-19, CV = 64) and negative (Control, CT = 37) groups and underwent protocol for skin imprint sample collection (see section below). A schematic representation of study design and patient summarized data is available in Figure 1.

Figure 1.
  • Download figure
  • Open in new tab
Figure 1.

Study design (a) and patient symptoms distributions and age characteristics (b). HRMS – high-resolution mass spectrometry, RT-PCR – reverse transcriptase-polymerase chain reaction.

Sample collection and preparation

Plates of silica gel 60 G (Merck, Darmstadt, Germany) with an area of 1 cm2 were used for skin imprint collection in a similar approach described for leprosy and cystic fibrosis screening18,19. The silica side of the plate was carefully positioned on patients’ left-back and gently pressed against the skin for 1 minute. No cleaning procedures were performed on the skin before sample collection. After the collection time, silica plates were stored in plastic tubes at −30°C until analysis. On the moment of analysis, silica plates were washed and covered with 500 µL of a Methanol:H2O (1:1) solution, agitated in vortex for 30 s, and left to decant for 5 minutes. A 200-µL aliquot of the supernatant was collected and ionized with formic acid (0.1% final concentration) before analysis.

High-Resolution Mass Spectrometry Analysis

Groups were randomized intra- and inter-daily and directly infused into a high-resolution ESI-Q-Exactive Orbitrap (Thermo Scientific, Germany) with 140,000 FWHM resolution on positive ion mode. Spectral data were acquired following the parameters: m/z range 150 - 1700, 10 acquisitions per sample, 40 scans per acquisition, flow injection rate 10 µl.min−1, capillary temperature 320°C, spray voltage 3.70 kV, nitrogen sheath gas 8 (arbitrary units), aux gas heater temperature 30°C, RF-lens 50, AGC target 106.

Statistical analysis and biomarker selection

Patient characteristics were expressed as the count followed by frequency (percentage) for categorical variables. Groups – infected and non-infected patients – were compared using Chi-Squared independent test or Fisher’s exact test, when applicable. For continuous variables (age, onset of symptoms) normality of data distribution was tested using Shapiro-Wilk test, and the median [interquartile range (IQR)] was attributed and analyzed using the Mann-Whitney hypothesis test. P-value was considered significant if < 0.05 two-tailed. A peak intensity table was extracted from acquired spectral data; a median value was attributed for each feature considering 10 replicates acquired per sample. Data was posteriorly normalized (quantile) and transformed (logarithm) before multivariate statistical analysis using MetaboAnalyst 5.0 online software (www.metaboanalyst.ca)21. A PLS-DA (Partial Least Square – Discriminant Analysis) was applied to the full dataset, aiming to elect a list of discriminant m/z features for molecule annotation. Using the VIP score list > as reference, we consulted METLIN (Scripps Center for Metabolomics, La Jolla, CA, USA – www.metlin.scripps.edu) and LIPIDMAPS (University of California, San Diego, CA, USA - www.lipidmaps.org) databases for molecule annotation with mass accuracy < 5 ppm. The model with the annotated biomarkers was evaluated through permutation tests (n = 1000). Fold-change values and p-value significances were attributed to each identified biomarker using volcano plot (t-test) resource. Markers were used to project a prediction models using a receiver operating characteristic curve (ROC) resource with a Linear SVM algorithm from MetaboAnalyst. Permutation tests (n = 1000) were employed to validate the refined model. R coding was used to draw the graphics.

RESULTS

Patient characteristics

The cohort described in this study recruited 101 patients from April 2020 to June 2020 that arrived at Clinics Hospital of the University of São Paulo reporting COVID-19 symptoms, from which 64 (63.4%) tested positive for SARS-COV-2. This population was female in its majority, on both COVID-19 and Control groups (59.4% and 78.4%, respectively), with a general median age of 45 (IQR 22) and 34 (IQR 21) years old (COVID-19 and Control, respectively). Time from the onset of symptoms to sample collection was longer in COVID-19 group (median 8, IQR 6) and differed from Control (median 5.5, IQR 4) with a p-value of 0.031. The most common reported symptoms in COVID-19 patients were fever (76.6%), dry cough (73.4), malaise (70.3%), and dyspnea (65.6%); however, significant difference (p-value < 0.05) between groups were observed only for fever, dyspnea, and anosmia/ageusia, that demonstrated higher prevalence among infected patients, while coryza and sore throat were significant to Controls. In the COVID-19 group, 43.8% of cases presented mild symptoms and were redirected to homecare; for hospitalized patients, 28.1% received noninvasive oxygen support, and 6.3% required invasive mechanical ventilation. Overall, 3 patients from the COVID-19 group (8.3%) deceased in the hospital. Significant differences (p-value < 0.05) were observed among groups regarding pre-existing comorbidities such as diabetes and hypertension, presenting higher prevalence on COVID-19 diagnosed group. Patients’ characteristics are summarized in Table 1.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1.

Demographic characteristics of enrolled patients.

Metabolomic analysis of skin imprint

We employed an untargeted metabolomic strategy to identify potential biomarkers present in the COVID-19 patient’s skin that may contribute to disease diagnosis and pathophysiology assessment. Hence, a full mass spectra dataset in the m/z range of 150 to 1,700 was normalized, transformed, and analyzed using a supervised multivariate analysis, PLS-DA. Figure 2a shows the supervised PLS-DA plot discriminating the Control from COVID-19 group. From the PLS-DA-associated VIP score list, we were able to annotate 14 markers, from which 7 were found increased in COVID-19 patients and 7 decreased (elevated in controls). Detailed characterization of annotated markers is displayed in Supporting information Table S1. The putative annotations of enhanced markers (Figure 2a) belong to the class of primary fatty acid amides (PFAM) (palmitic amide, linoleamide, and oleamide), N-acylethanolamines (NAE) (palmitoleoyl-ethanolamide, POEA), N-acyl amino acids (N-palmitoyl threonine), and glycerolipids (a triacylglycerol (TG(24:0)) and a diacylglycerol (DG(40:10))). In contrast, decreased biomarkers consisted of phosphatidylserines (PS(34:0), PS(40:5), and PS(P-38:5)), dipeptides (cysteinyl-glutamine, valyl-arginine), and sterol lipids (cortisol and trihydroxyvitamin D3). Permutation tests (p-value < 0.001) were used to evaluate model predictability (data shown on Supporting information Figure S1).

Figure 2.
  • Download figure
  • Open in new tab
Figure 2.

PLS-DA plot discriminated COVID-19 from Control group with listed annotated markers according to log2(FC) and p- value, and AUC (a). A ROC curve using Oleamide data, the most prominent marker ranked by AUC and a multivariate ROC curve was used to evaluate the influence of variable number (b) on model performance (c).

The importance of markers is ordered according to the fold-change of relative intensities from COVID-19 over the Control group, with associated p-value and area under curve (AUC) (Figure 2a). Oleamide, linoleamide, DG(40:10) for COVID-19 group and cysteinyl-glutamine and PS(34:0) for Control group presented significant alterations in the fold-change of their m/z feature intensities (p-value < 0.01). Even though linoleamide presented the highest difference in fold-change, oleamide exhibited the upmost AUC (0.873) (Figure 2b). Oleamide normalized intensities in COVID-19 and Control were used to project curve with a 95% of Confidence Interval from 0.797 to 0.946. The ROC model (Figure 2b) achieved a predicted accuracy of 76.6%, and calculated specificity and sensitivity of 79.0% and 76.9%, respectively; the model was validated by 1000 permutations (empiric p-value < 0.001). A multivariate receiver operating characteristic (ROC) was projected using 2, 3, 5, 7, 10 and 14 markers as variables (Figure 2b). The performance obtained with oleamide, 2 variables, 3 variables and all markers are exemplified in Figure 2c and detailed in Figure S2 e S3 available as supporting information. While the oleamide demonstrated the best sensitivity (79.0%), the highest specificity was obtained with 3 features (84.6%).

DISCUSSION

COVID-19 has been pointed to as a multifactorial disease with multi-organ implications, especially due to the broad distribution of SARS-CoV-2 binding receptor, ACE214. While the impairment of respiratory, nervous, cardiovascular, and gastrointestinal systems has been widely explored, skin involvement only gained notoriety with the increased reporting of skin lesions14,15,17,22. Xue et al. (2020) demonstrated that keratinocytes expressed high levels of ACE2, in particular differentiating keratinocytes and basal cells, while sweat gland cells presented moderate expression15. These findings suggested the importance of further investigation on the involvement of skin barrier during SARS-CoV-2 infection15. In addition to clinical and histopathological profiling of skin manifestations, metabolic alterations presented in normal skin of COVID-19 patients and the pathogenic mechanisms of the virus in this organ were little explored 12,22,23.

In a pilot study with 67 participants, Spick et al. (2021) demonstrated that the sebum lipidome of COVID-19 normal skin presented alterations in ceramides and glycerolipids when compared to controls. Particularly, a decrease in triacyglycerol levels was perceived, implying the importance of this biofluid for diagnostic testing 12. In our analysis, TG(24:0) and DG(40:10) were the representants of glycerolipids class and were decreased in the skin imprint of COVID-19 patients. Disrupted lipid metabolism is a common feature in viral infection, and particularly for COVID-19, altered levels of glycerolipids are associated with the presence and severity of SARS-CoV-2 infection on plasma and serum samples4,5,8,9. Among other lipid species, phosphatidylserines were cited as decreased metabolites in COVID-195,10,11,13. Four previous studies reported reduced levels of PS in COVID-19 cases5,11, even when mild10, moderate and severe13 cases were compared to controls, on both blood-derived samples5,10,13 and naso-oropharyngeal swabs11, corroborating our findings. PS is a negatively-charged membrane phospholipid that may translocate from inner to outer cell membrane layer in early stages of viral infection24,25. It functions as a signal for macrophages cell phagocytoses and may also occur during platelet activation to contribute to the inflammatory and coagulopathy patterns observed in COVID-1924,25. Zaid et al. (2020) noticed a significant increase in platelet extracellular vesicles in patients with COVID-19 compared to healthy subjects, and a decrease in severe cases against mild manifestations. Besides, platelet EV exposing PS were significantly enhanced in non-severe symptoms, which may suggest its consumption and depletion in severe cases25.

In addition to other lipid classes, elevated PFAMs (palmitic amide, linoleamide, and oleamide) and NAE (palmitoleoyl-ethanolamide) species were interesting findings observed on COVID-19 group when compared to Controls. Fatty acid amides are part of the complex endocannabinoid system, and the biological mechanisms of several species are not fully elucidated26. However, in general, these bioactive lipids present relevant neuromodulatory and immune properties26. Even the cannabinoid receptor-inactive NAEs and PFAMs exert influence in the interaction of active endocannabinoids (e.g. anandamide) with receptors (CB1 and CB2). Due to site competition, cannabinoid receptor-inactive NAEs and PFAMs may delay the active molecules inactivation via FAAH (fatty acid amide hydrolase) and transport, keeping active forms available for longer time to interact with CB receptors26,27. While CB1 is primarily found in the brain and nervous tissues, CB2 is expressed in varied types of skin tissue cells (basal keratinocytes) and annexes (sweat gland duct, undifferentiated sebaceous cells, and undifferentiated infundibular hair follicle cells), in addition to immune cells (mast cells, monocytes/macrophages, B and T lymphocytes) showing a role in immunomodulation27–29. The immunosuppressive effect of CB2 receptors leads to a depletion of immune cell recruitment, macrophage polarization, modulation of T helper cells 1 and 2 activities, and proinflammatory cytokines and chemokines release28,30,31. Due to these immunosuppressive activities, the CB2 receptor has been pointed as a potential therapeutic target in COVID-19 management of cytokine storm30,31. However, the extent of immunomodulation should be carefully evaluated based on the SARS-CoV-2 infection timeline, since it may influence viral pathogenesis outcome28,30.

Oleamide, the most prominent marker found in our study is a bioactive PFAM metabolized by the FAAH enzyme26. Together with linoleamide, oleamide is known as a sleep-inducing agent, interacting with the GABA system26, Ca2+ transport modulation26,32, in addition to being a selective endogenous agonist of human CB1 receptor33,34. The exact mechanism by which oleamide promotes its biological function within the endocannabinoid system remains unclear, and so the allosteric regulation of CB1/CB2 has not been discarded27,34. Even though their bioactivity is associated with nervous and immune system stimulation, fatty acid amides have been detected in urine, plasma, sweat, and saliva35. Both linoleamide and oleamide were previously reported as markers of COVID-19 in nasal- and oropharyngeal samples when analyzed using paper-spray mass spectrometry technique11. In our study, the increase of oleamide alone in the COVID-19 patients’ skin achieved a good performance as a predictor of the disease, with specificity of 76.9% and sensitivity of 79.0%, reassuring its potential as a COVID-19 diagnosis biomarker.

Two other lipid metabolites, trihydroxyvitamin D3 and cortisol, were found in lower amounts on the skin imprint of COVID-19 patients. Several factors, such as stress, treatment, food supplementation, age, ethnicity, and latitude may influence sterols concentration, and therefore reliable levels of these substances to be considered as potential biomarkers for SARS-CoV-2 infection remain controversial and requires further data collection and validation36–38.

Altogether, the elected markers presented good specificity (82.1%) and sensitivity (74.2%) for COVID-19 screening, reinforcing the potential of alternative sampling methods for diagnostic tests. Even though markers were found correlated with some of the SARS-CoV-2 previously reported alterations, this cohort was enrolled in the first phase of Brazilian COVID-19 pandemic, and therefore, the investigation and validation of the results with a new sampling from the second wave may be appropriate. Most patients presented mild and moderate symptoms, with a low rate of invasive mechanical ventilation support and number of deceased patients. This demonstrates that the method was sensitive enough to discriminate COVID-19 from patients with mild flu-like symptoms. However, the incorporation of more severe cases would be beneficial for a tentative risk stratification as a future direction.

CONCLUSION

The continued use of metabolomics as an approach for problem-solving in many fields of knowledge is providing insights of conditions and diseases at the biomolecular level. This information may serve as foundation, as well as validation of further studies and techniques. Our study aims to provide an overview on how the skin biochemistry is impacted by COVID-19 infection, demonstrating the main biomarkers present in this scenario, as well as the possible pathways affected by the biochemical disbalance, which may impact the endocannabinoid and immune system. Further investigation is required to pinpoint the actual causes and agents that are related to the widespread organ impairment in COVID-19 infection as an effort to provide better understanding and strategies to fight back this condition.

Data Availability

Biomarkers elucidation data through mass spectrometry is available as supporting information Pre-processed mass spectrometry data will be available at Zenodo following publication. De-identified patient information will be made available from corresponding author upon request.

ASSOCIATED CONTENT

Supporting Information

  • Biomarker’s elucidation data through mass spectrometry (PDF).

  • Pre-processed mass spectrometry data will be available at Zenodo following publication.

  • De-identified patient information will be made available from corresponding author upon request.

AUTHOR INFORMATION

Corresponding Author

* RRC - rrc{at}unicamp.br, phone +55 19 3521-9138

AUTHOR CONTRIBUTIONS

RFS, JCN, TFD, AJB, ECS, MWPJ, LOR, ND, WJF, JD, and RRC were involved with study design. RFS, JCN, TFD, AJB, RS, FGM-B, ECS, AE, MWPJ, LOR, WJF, ND and LAS contributed to patient sample and data collection, clinical support, and network feasibility. JD, ENBB, GMS, ANO, DNO performed mass spectrometry experiments and data interpretation. JD and ANO performed data analysis and wrote the manuscript. DNO, RFS, JCN, MWPJ, ND, WJF and RRC revised the manuscript. RRC idealized the project and managed the research group. All authors approved the manuscript.

Competing Interests

The authors declare no conflict of interests.

ACKNOWLEDGMENTS

The authors would like to thank the network involved in sample collection, clinical data curation and diagnosis, in special to Paulínia Municipal Hospital and Sumaré State Hospital (CAAE 31049320.7.1001.5404) for providing samples to the initial steps of method development, and Thermo Scientific and LADETEC (UFRJ) for the technology support. This work was supported by São Paulo Research Foundation (FAPESP) [2019/05718-3 to JD, 2018/10052-1 to WJF, 2020/04705-2 to JCN and TFD], and Coordination for the Improvement of Higher Education Personnel (CAPES) [88887.513974/2020-00 to ANO].

REFERENCES

  1. (1).↵
    Flaxman, S., Mishra, S., Gandy, A., Unwin, H. J. T., Mellan, T. A., Coupland, H., Whittaker, C., Zhu, H., Berah, T., Eaton, J. W., Monod, M., Perez-Guzman, P. N., Schmit, N., Cilloni, L., Ainslie, K. E. C., Baguelin, M., Boonyasiri, A., Boyd, O., Cattarino, L., Cooper, L. v., Cucunubá, Z., Cuomo-Dannenburg, G., Dighe, A., Djaafara, B., Dorigatti, I., van Elsland, S. L., FitzJohn, R. G., Gaythorpe, K. A. M., Geidelberg, L., Grassly, N. C., Green, W. D., Hallett, T., Hamlet, A., Hinsley, W., Jeffrey, B., Knock, E., Laydon, D. J., Nedjati-Gilani, G., Nouvellet, P., Parag, K. v., Siveroni, I., Thompson, H. A., Verity, R., Volz, E., Walters, C. E., Wang, H., Wang, Y., Watson, O. J., Winskill, P., Xi, X., Walker, P. G. T., Ghani, A. C., Donnelly, C. A., Riley, S., Vollmer, M. A. C., Ferguson, N. M., Okell, L. C., Bhatt, S. Estimating the Effects of Non-Pharmaceutical Interventions on COVID-19 in Europe. Nature 2020, 584 (7820), 257–261. https://doi.org/10.1038/s41586-020-2405-7.
    OpenUrlPubMed
  2. (2).↵
    Jose, R. J., Manuel, A. COVID-19 Cytokine Storm: The Interplay between Inflammation and Coagulation. The Lancet Respiratory Medicine 2020, 8 (6), e46–e47. https://doi.org/10.1016/S2213-2600(20)30216-2.
    OpenUrl
  3. (3).↵
    Caterino, M., Gelzo, M., Sol, S., Fedele, R., Annunziata, A., Calabrese, C., Fiorentino, G., D’Abbraccio, M., Dell’Isola, C., Fusco, F. M., Parrella, R., Fabbrocini, G., Gentile, I., Andolfo, I., Capasso, M., Costanzo, M., Daniele, A., Marchese, E., Polito, R., Russo, R., Missero, C., Ruoppolo, M., Castaldo, G. Dysregulation of Lipid Metabolism and Pathological Inflammation in Patients with COVID-19. Scientific Reports 2021, 11 (1), 1–10. https://doi.org/10.1038/s41598-021-82426-7.
    OpenUrl
  4. (4).↵
    Shen, B., Yi, X., Sun, Y., Bi, X., Du, J., Zhang, C., Quan, S., Zhang, F., Sun, R., Qian, L., Ge, W., Liu, W., Liang, S., Chen, H., Zhang, Y., Li, J., Xu, J., He, Z., Chen, B., Wang, J., Yan, H., Zheng, Y., Wang, D., Zhu, J., Kong, Z., Kang, Z., Liang, X., Ding, X., Ruan, G., Xiang, N., Cai, X., Gao, H., Li, L., Li, S., Xiao, Q., Lu, T., Zhu, Y., Liu, H., Chen, H., Guo, T. Proteomic and Metabolomic Characterization of COVID-19 Patient Sera. Cell 2020, 182 (1), 59–72. https://doi.org/10.1016/j.cell.2020.05.032.
    OpenUrlCrossRefPubMed
  5. (5).↵
    Delafiori, J., Navarro, L. C., Siciliano, R. F., de Melo, G. C., Busanello, E. N. B., Nicolau, J. C., Sales, G. M., de Oliveira, A. N., Val, F. F. A., de Oliveira, D. N., Eguti, A., dos Santos, L. A., Dalçóquio, T. F., Bertolin, A. J., Abreu-Netto, R. L., Salsoso, R., Baía-Da-Silva, D., Marcondes-Braga, F. G., Sampaio, V. S., Judice, C. C., Costa, F. T. M., Durán, N., Perroud, M. W., Sabino, E. C., Lacerda, M. V. G., Reis, L. O., Fávaro, W. J., Monteiro, W. M., Rocha, A. R., Catharino, R. R. Covid-19 Automated Diagnosis and Risk Assessment through Metabolomics and Machine Learning. Analytical Chemistry 2021, 93 (4), 2471–2479. https://doi.org/10.1021/acs.analchem.0c04497.
    OpenUrl
  6. (6).↵
    Grassin-Delyle, S., Roquencourt, C., Moine, P., Saffroy, G., Carn, S., Heming, N., Fleuriet, J., Salvator, H., Naline, E., Couderc, L. J., Devillier, P., Thévenot, E. A., Annane, D. Metabolomics of Exhaled Breath in Critically Ill COVID-19 Patients: A Pilot Study. EBioMedicine 2021, 63, 103154–undefined. https://doi.org/10.1016/j.ebiom.2020.103154.
    OpenUrl
  7. (7).↵
    Costa Dos Santos Junior, G., Pereira, C. M., Kelly Da Silva Fidalgo, T., Valente, A. P. Saliva NMR-Based Metabolomics in the War against COVID-19. Analytical Chemistry 2020, 92 (24), 15688–15692. https://doi.org/10.1021/acs.analchem.0c04679.
    OpenUrl
  8. (8).↵
    Su, Y., Chen, D., Yuan, D., Lausted, C., Choi, J., Dai, C. L., Voillet, V., Duvvuri, V. R., Scherler, K., Troisch, P., Baloni, P., Qin, G., Smith, B., Kornilov, S. A., Rostomily, C., Xu, A., Li, J., Dong, S., Rothchild, A., Zhou, J., Murray, K., Edmark, R., Hong, S., Heath, J. E., Earls, J., Zhang, R., Xie, J., Li, S., Roper, R., Jones, L., Zhou, Y., Rowen, L., Liu, R., Mackay, S., O’Mahony, D. S., Dale, C. R., Wallick, J. A., Algren, H. A., Zager, M. A., Wei, W., Price, N. D., Huang, S., Subramanian, N., Wang, K., Magis, A. T., Hadlock, J. J., Hood, L.; Aderem, A., Bluestone, J. A., Lanier, L. L., Greenberg, P. D., Gottardo, R., Davis, M. M., Goldman, J. D., Heath, J. R. Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19. Cell 2020, 183 (6), 1479–1495. https://doi.org/10.1016/j.cell.2020.10.037.
    OpenUrlPubMed
  9. (9).↵
    Wu, D., Shu, T., Yang, X., Song, J.-X., Zhang, M., Yao, C., Liu, W., Huang, M., Yu, Y., Yang, Q., Zhu, T., Xu, J., Mu, J., Wang, Y., Wang, H., Tang, T., Ren, Y., Wu, Y., Lin, S.-H., Qiu, Y., Zhang, D. Y., Shang, Y., Zhou, X. Plasma Metabolomic and Lipidomic Alterations Associated with COVID-19. National Science Review 2020, 7 (7), 1157–1168. https://doi.org/10.1093/nsr/nwaa086.
    OpenUrl
  10. (10).↵
    Song, J. W., Lam, S. M., Fan, X., Cao, W. J., Wang, S. Y., Tian, H., Chua, G. H., Zhang, C., Meng, F. P., Xu, Z., Fu, J. L., Huang, L., Xia, P., Yang, T., Zhang, S., Li, B., Jiang, T. J., Wang, R., Wang, Z., Shi, M., Zhang, J. Y., Wang, F. S., Shui, G. Omics-Driven Systems Interrogation of Metabolic Dysregulation in COVID-19 Pathogenesis. Cell Metabolism 2020, 32 (2), 188–202. https://doi.org/10.1016/j.cmet.2020.06.016.
    OpenUrl
  11. (11).↵
    de Silva, I. W., Nayek, S., Singh, V., Reddy, J., Granger, J. K., Verbeck, G. F. Paper Spray Mass Spectrometry Utilizing Teslin® Substrate for Rapid Detection of Lipid Metabolite Changes during COVID-19 Infection. Analyst 2020, 145 (17), 5725–5732. https://doi.org/10.1039/d0an01074j.
    OpenUrl
  12. (12).↵
    Spick, M., Longman, K., Frampas, C., Lewis, H., Costa, C., Walters, D. D., Stewart, A., Wilde, M., Greener, D., Evetts, G., Trivedi, D., Barran, P., Pitt, A., Bailey, M. Changes to the Sebum Lipidome upon COVID-19 Infection Observed via Rapid Sampling from the Skin. EClinicalMedicine 2021, 33, 100786–undefined. https://doi.org/10.1016/j.eclinm.2021.100786.
    OpenUrl
  13. (13).↵
    Schwarz, B., Sharma, L., Roberts, L., Peng, X., Bermejo, S., Leighton, I., Casanovas-Massana, A., Minasyan, M., Farhadian, S., Ko, A. I., dela Cruz, C. S., Bosio, C. M. Cutting Edge: Severe SARS-CoV-2 Infection in Humans Is Defined by a Shift in the Serum Lipidome, Resulting in Dysregulation of Eicosanoid Immune Mediators. The Journal of Immunology 2021, 206 (2), 329– 334. https://doi.org/10.4049/jimmunol.2001025.
    OpenUrl
  14. (14).↵
    Garg, S., Garg, M., Prabhakar, N., Malhotra, P., Agarwal, R. Unraveling the Mystery of Covid-19 Cytokine Storm: From Skin to Organ Systems. Dermatologic Therapy 2020, 33 (6), e13859–undefined. https://doi.org/10.1111/dth.13859.
    OpenUrl
  15. (15).↵
    Xue, X., Mi, Z., Wang, Z., Pang, Z., Liu, H., Zhang, F. High Expression of ACE2 on Keratinocytes Reveals Skin as a Potential Target for SARS-CoV-2. Journal of Investigative Dermatology 2021, 141 (1), 206–209. https://doi.org/10.1016/j.jid.2020.05.087.
    OpenUrl
  16. (16).↵
    Guarneri, C., Rullo, E. V., Pavone, P., Berretta, M., Ceccarelli, M., Natale, A., Nunnari, G. Silent COVID-19: What Your Skin Can Reveal. The Lancet Infectious Diseases 2021, 21 (1), 24–25. https://doi.org/10.1016/S1473-3099(20)30402-3.
    OpenUrl
  17. (17).↵
    Genovese, G., Moltrasio, C., Berti, E., Marzano, A. V. Skin Manifestations Associated with COVID-19: Current Knowledge and Future Perspectives. Dermatology 2021, 237 (1), 1–12. https://doi.org/10.1159/000512932.
    OpenUrlPubMed
  18. (18).↵
    Lima, E. D. O., de Macedo, C. S., Esteves, C. Z., de Oliveira, D. N., Pessolani, M. C. V., Nery, J. A. D. C., Sarno, E. N., Catharino, R. R. Skin Imprinting in Silica Plates: A Potential Diagnostic Methodology for Leprosy Using High-Resolution Mass Spectrometry. Analytical Chemistry 2015, 87 (7), 3585–3592. https://doi.org/10.1021/acs.analchem.5b00097.
    OpenUrl
  19. (19).↵
    Esteves, C. Z., Dias, L. de A., Lima, E. de O., Oliveira, D. N. de; Odir Rodrigues Melo, C. F., Delafiori, J., Souza Gomez, C.C., Ribeiro, J. D., Ribeiro, A. F., Levy, C. E., Catharino, R. R. Skin Biomarkers for Cystic Fibrosis: A Potential Non-Invasive Approach for Patient Screening. Frontiers in Pediatrics 2018, 5, 290–undefined. https://doi.org/10.3389/fped.2017.00290.
    OpenUrl
  20. (20).↵
    Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K. W., Bleicker, T., Brünink, S., Schneider, J., Schmidt, M. L., Mulders, D. G. J. C., Haagmans, B. L., van der Veer, B., van den Brink, S., Wijsman, L., Goderski, G., Romette, J. L., Ellis, J., Zambon, M., Peiris, M., Goossens, H., Reusken, C., Koopmans, M. P. G., Drosten, C. Detection of 2019 Novel Coronavirus (2019-NCoV) by Real-Time RT-PCR. Eurosurveillance 2020, 25 (3), 2000045–undefined. https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045.
    OpenUrl
  21. (21).↵
    Chong, J., Wishart, D. S., Xia, J. Using MetaboAnalyst 4.0 for Comprehensive and Integrative Metabolomics Data Analysis. Current Protocols in Bioinformatics 2019, 68 (1), e86–undefined. https://doi.org/10.1002/cpbi.86.
    OpenUrlCrossRefPubMed
  22. (22).↵
    Recalcati, S. Cutaneous Manifestations in COVID-19: A First Perspective. Journal of the European Academy of Dermatology and Venereology 2020, 34 (5), e212–e213. https://doi.org/10.1111/jdv.16387.
    OpenUrlPubMed
  23. (23).↵
    Novak, N., Peng, W., Naegeli, M. C., Galvan, C., Kolm-Djamei, I., Brüggen, C., Cabanillas, B., Schmid-Grendelmeier, P., Catala, A. SARS-CoV-2, COVID-19, Skin and Immunology – What Do We Know so Far? Allergy: European Journal of Allergy and Clinical Immunology 2020, 76 (3), 698–713. https://doi.org/10.1111/all.14498.
    OpenUrl
  24. (24).↵
    Argañaraz, G. A., Palmeira, J. da F., Argañaraz, E. R. Phosphatidylserine inside out: A Possible Underlying Mechanism in the Inflammation and Coagulation Abnormalities of COV ID-19. Cell Communication and Signaling 2020, 18 (1), 1–10. https://doi.org/10.1186/s12964-020-00687-7.
    OpenUrl
  25. (25).↵
    Zaid, Y., Puhm, F., Allaeys, I., Naya, A., Oudghiri, M., Khalki, L., Limami, Y., Zaid, N., Sadki, K., ben El Haj, R., Mahir, W., Belayachi, L., Belefquih, B., Benouda, A., Cheikh, A., Langlois, M. A., Cherrah, Y., Flamand, L., Guessous, F., Boilard, E. Platelets Can Associate with SARS - CoV-2 RNA and Are Hyperactivated in COVID-19. Circulation Research 2020, 127 (11), 1404– 1418. https://doi.org/10.1161/CIRCRESAHA.120.317703.
    OpenUrlPubMed
  26. (26).↵
    Hiley, C. R., Hoi, P. M. Oleamide: A Fatty Acid Amide Signaling Molecule in the Cardiovascular System? Cardiovascular Drug Reviews 2007, 25 (1), 46–60. https://doi.org/10.1111/j.1527-3466.2007.00004.x.
    OpenUrlCrossRefPubMedWeb of Science
  27. (27).↵
    Fonseca, B. M., Costa, M. A., Almada, M., Correia-Da-Silva, G., Teixeira, N. A. Endogenous Cannabinoids Revisited: A Biochemistry Perspective. Prostaglandins and Other Lipid Mediators 2013, 102, 13–30. https://doi.org/10.1016/j.prostaglandins.2013.02.002.
    OpenUrl
  28. (28).↵
    Sipe, J. C., Arbour, N., Gerber, A., Beutler, E. Reduced Endocannabinoid Immune Modulation by a Common Cannabinoid 2 (CB2) Receptor Gene Polymorphism: Possible Risk for Autoimmune Disorders. Journal of Leukocyte Biology 2005, 78 (1), 231–238. https://doi.org/10.1189/jlb.0205111.
    OpenUrlCrossRefPubMedWeb of Science
  29. (29).↵
    Ständer, S., Schmelz, M., Metze, D., Luger, T., Rukwied, R. Distribution of Cannabinoid Receptor 1 (CB1) and 2 (CB2) on Sensory Nerve Fibers and Adnexal Structures in Human Skin. Journal of Dermatological Science 2005, 38 (3), 177–188. https://doi.org/10.1016/j.jdermsci.2005.01.007.
    OpenUrlCrossRefPubMedWeb of Science
  30. (30).↵
    Nagoor Meeran, M. F., Sharma, C., Goyal, S. N., Kumar, S., Ojha, S. CB2 Receptor-Selective Agonists as Candidates for Targeting Infection, Inflammation, and Immunity in SARS-CoV-2 Infections. Drug Development Research 2020, 82 (1), 7–11. https://doi.org/10.1002/ddr.21752.
    OpenUrl
  31. (31).↵
    Rossi, F., Tortora, C., Argenziano, M., di Paola, A., Punzo, F. Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection? International Journal of Molecular Sciences 2020, 21 (11), 3809–undefined. https://doi.org/10.3390/ijms21113809.
    OpenUrl
  32. (32).↵
    Lo, Y. K., Tang, K. Y., Chang, W. N., Lu, C. H., Cheng, J. S., Lee, K. C., Chou, K. J., Liu, C. P., Chen, W. C., Su, W., Law, Y. P., Jan, C. R. Effect of Oleamide on Ca2+ Signaling in Human Bladder Cancer Cells. Biochemical Pharmacology 2001, 62 (10), 1363–1369. https://doi.org/10.1016/S0006-2952(01)00772-9.
    OpenUrlCrossRefPubMed
  33. (33).↵
    Leggett, J. D., Aspley, S., Beckett, S. R. G., D’Antona, A. M., Kendall, D. A., Kendall, D. A. Oleamide Is a Selective Endogenous Agonist of Rat and Human CB 1 Cannabinoid Receptor s. British Journal of Pharmacology 2004, 141 (2), 253–262. https://doi.org/10.1038/sj.bjp.0705607.
    OpenUrlCrossRefPubMedWeb of Science
  34. (34).↵
    Hernández-Cervantes, R., Méndez-Díaz, M., Prospéro-García, Ó., Morales-Montor, J. Immunoregulatory Role of Cannabinoids during Infectious Disease. NeuroImmunoModulation 2018, 24 (4–5), 183–199. https://doi.org/10.1159/000481824.
    OpenUrl
  35. (35).↵
    Castillo-Peinado, L. S., López-Bascón, M. A., Mena-Bravo, A., Luque de Castro, M. D., Priego-Capote, F. Determination of Primary Fatty Acid Amides in Different Biological Fluids by LC – MS/MS in MRM Mode with Synthetic Deuterated Standards: Influence of Biofluid Matrix on Sample Preparation. Talanta 2019, 193, 29–36. https://doi.org/10.1016/j.talanta.2018.09.088.
    OpenUrl
  36. (36).↵
    Rhodes, J. M., Subramanian, S., Laird, E., Griffin, G., Kenny, R. A. Perspective: Vitamin D Deficiency and COVID-19 Severity – Plausibly Linked by Latitude, Ethnicity, Impacts on Cytokines, ACE2 and Thrombosis. Journal of Internal Medicine 2021, 289 (1), 97–115. https://doi.org/10.1111/joim.13149.
    OpenUrl
  37. (37).
    Tan, T., Khoo, B., Mills, E. G., Phylactou, M., Patel, B., Eng, P. C., Thurston, L., Muzi, B., Meeran, K., Prevost, A. T., Comninos, A. N., Abbara, A., Dhillo, W. S. Association between High Serum Total Cortisol Concentrations and Mortality from COVID-19. The Lancet Diabetes and Endocrinology. 2020, pp 659–660. https://doi.org/10.1016/S2213-8587(20)30216-3.
  38. (38).↵
    Slominski, R. M., Stefan, J., Athar, M., Holick, M. F., Jett en, A. M, Slominski, A., Raman, C.. T. COVID-19 and Vitamin D: A Lesson from the Skin. Experimental Dermatology 2020, 29 (9), 885–890. https://doi.org/10.1111/exd.14170.
    OpenUrl
Back to top
PreviousNext
Posted April 20, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Skin imprints to provide noninvasive metabolic profiling of COVID-19 patients
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Skin imprints to provide noninvasive metabolic profiling of COVID-19 patients
Jeany Delafiori, Rinaldo Focaccia Siciliano, Arthur Noin de Oliveira, José Carlos Nicolau, Geovana Manzan Sales, Talia Falcão Dalçóquio, Estela Natacha Brandt Busanello, Adriana Eguti, Diogo Noin de Oliveira, Adriadne Justi Bertolin, Luiz Augusto dos Santos, Rocío Salsoso, Fabiana G Marcondes-Braga, Nelson Durán, Maurício Wesley Perroud Júnior, Ester Cerdeira Sabino, Leonardo Oliveira Reis, Wagner José Fávaro, Rodrigo Ramos Catharino
medRxiv 2021.04.17.21255518; doi: https://doi.org/10.1101/2021.04.17.21255518
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Skin imprints to provide noninvasive metabolic profiling of COVID-19 patients
Jeany Delafiori, Rinaldo Focaccia Siciliano, Arthur Noin de Oliveira, José Carlos Nicolau, Geovana Manzan Sales, Talia Falcão Dalçóquio, Estela Natacha Brandt Busanello, Adriana Eguti, Diogo Noin de Oliveira, Adriadne Justi Bertolin, Luiz Augusto dos Santos, Rocío Salsoso, Fabiana G Marcondes-Braga, Nelson Durán, Maurício Wesley Perroud Júnior, Ester Cerdeira Sabino, Leonardo Oliveira Reis, Wagner José Fávaro, Rodrigo Ramos Catharino
medRxiv 2021.04.17.21255518; doi: https://doi.org/10.1101/2021.04.17.21255518

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)